




Review Article



The Power of Probiotics to Combat Urinary Tract Infections: A Comprehensive Review

Ali Qasemi^{1,*}, Milad Lagzian¹, Fateh Rahimi², Foad Khosravani Majd³, and Zeynab Bayat⁴ 

¹ Department of Biology, Faculty of Science, University of Sistan and Baluchestan, Zahedan, Iran

² Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Zahedan, Iran

³ Department of Food Science and Technology, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran

⁴ Department of Biology, Faculty of Sciences, Shahid Bahonar University of Kerman, Kerman, Iran

* **Corresponding author:** Ali Qasemi, Department of Biology, Faculty of Science, University of Sistan and Baluchestan, Zahedan, Iran.

Email: qasemi.ali9@gmail.com

ARTICLE INFO

Article History:

Received: 08/11/2022

Accepted: 15/02/2023



Keywords:

Efficacy

Probiotics

Treatment

Urinary tract infections

ABSTRACT

Urinary tract infections (UTIs) are among the most common bacterial infections and can cause significant morbidity, particularly in women. Recurrent UTIs are a significant clinical problem, and current prophylactic measures, such as antibiotics, are associated with side effects and the risk of antimicrobial resistance. Probiotics, defined as live microorganisms that confer health benefits to the host, have emerged as a potential alternative to traditional treatments for recurrent UTIs.

Probiotics can act by modulating the host's immune system, competitively excluding uropathogens, and producing antibacterial substances, such as bacteriocins. Clinical evidence supports the use of probiotics as a safe and effective intervention for the prevention and treatment of recurrent UTIs. However, selecting appropriate probiotic strains for UTIs can be challenging, and the safety and efficacy of probiotics depend on the strain, dosage, and timing of administration.

The safety profile of probiotics is generally excellent, and side effects are usually mild and self-limiting. However, certain populations, such as immunocompromised and critically ill patients, may be at increased risk of adverse events, and caution should be exercised when considering probiotic use in these populations. Strategies for ensuring probiotic safety and efficacy include adherence to good manufacturing practices, rigorous testing for the presence of contaminants, and standardization of dosing and administration protocols.

Despite the potential of probiotics for the prevention and treatment of recurrent UTIs, several challenges and limitations remain. These include limited access to high-quality probiotic products, challenges in selecting appropriate strains, and lack of consensus regarding optimal dosing and duration of probiotic use. Future research should focus on identifying optimal probiotic strains and regimens for the prevention and treatment of UTIs, understanding the role of gut microbiota in urogenital health, and developing new probiotic technologies and delivery methods.

1. Introduction

1.1. Urinary tract infections

Urinary tract infections (UTIs) are among the prevalent bacterial infections worldwide, with a significant impact on both individual health and healthcare costs¹. They occur when bacteria, usually from the intestinal microbiota, enter the urinary tract and multiply, causing inflammation and tissue damage². The UTIs can happen in any part of the urinary system, from the bladder to the kidneys, and can

range in severity from mild discomfort to life-threatening sepsis². Women are at higher risk of UTIs than men, due to anatomical and hormonal factors, and recurrent UTIs are a common problem, affecting up to 25% of women who experience an initial UTI³.

The most common causative agent of UTIs is *Escherichia coli* (*E. coli*), a gram-negative bacterium that colonizes the rectal and perineal areas⁴. Other bacteria that can cause UTIs include *Klebsiella pneumoniae*, *Proteus*

mirabilis, and *Staphylococcus saprophyticus*⁴. Risk factors for UTIs include female gender, sexual activity, use of spermicides or diaphragms, urinary tract abnormalities, and impaired immune function. The UTIs can also be caused by catheterization or other medical procedures introducing bacteria into the urinary tract^{3,4}.

Antibiotics are the mainstay of UTI treatment, but the emergence of antibiotic-resistant strains of bacteria has led to increasing interest in alternative approaches, such as probiotics⁵. Probiotics are live microorganisms that confer health benefits when consumed in adequate amounts⁵. They can help prevent UTIs by competing with pathogenic bacteria for resources, producing antibacterial substances, and modulating the host immune response⁶. Probiotics can also be used as a treatment for UTIs, either alone or in combination with antibiotics⁷. While there is growing evidence for the efficacy of probiotics in preventing and treating UTIs, challenges remain in determining the optimal probiotic strains, dosages, and administration routes, as well as ensuring their safety and quality^{6,7}.

1.2. The role of probiotics in the prevention and treatment of urinary tract infections

Probiotics are defined as live microorganisms that, when administered in adequate amounts, confer health benefits to the host⁸. They are commonly found in fermented foods and dietary supplements and can contain various bacterial and fungal species⁸. Probiotics can exert their effects through several mechanisms, including direct competition with pathogenic bacteria for resources, antibacterial substances production, and host immune response modulation. The use of probiotics to prevent and treat UTIs has gained increasing attention due to the limitations of conventional antibiotic therapy⁹.

The mechanisms by which probiotics can prevent UTIs include the production of antimicrobial peptides, modulation of the host immune response, and the ability to compete with pathogenic bacteria for adherence to the urinary tract mucosa^{9,10}. *Lactobacilli* and *Bifidobacteria* are two of the most commonly studied probiotic strains for UTI prevention, as they are natural colonizers of the human gut and vaginal microbiota¹⁰. These strains have been indicated to produce hydrogen peroxide, which can inhibit the growth of uropathogenic bacteria, and to enhance mucus production in the urinary tract, which can physically prevent bacterial adhesion¹⁰.

Probiotics can also be used as an adjunct to antibiotic therapy for treating UTIs, as they can help replenish the normal microbiota and reduce the risk of recurrent infections¹¹. One study found that using *Lactobacillus crispatus* vaginal suppositories in combination with antibiotics was associated with a lower risk of recurrent UTIs compared to antibiotic therapy alone¹¹. Another study indicated that the use of *Lactobacillus rhamnosus* (*L. rhamnosus*) GG reduced the risk of antibiotic-associated diarrhea and other adverse effects in patients with UTIs¹². However, further investigation is required to determine the optimal probiotic strains, dosages, and administration

routes for UTI treatment.

1.3. Purpose of study

The purpose of this study is to provide a comprehensive overview of the current knowledge regarding the apply of probiotics for the prevention and treatment of urinary tract infections (UTIs). The article will begin with background information on UTIs, including their causes, risk factors, and current treatment options. The definition of probiotics and their role in the prevention and treatment of UTIs will then be discussed, focusing on the mechanisms by which probiotics can prevent and treat UTIs, as well as the most commonly studied probiotic strains. In addition, the safety and quality of probiotic supplements will also be discussed, as well as the potential of probiotics to reduce the use of antibiotics and the emergence of antibiotic-resistant bacteria will be explored, as well as the economic implications of probiotic therapy for UTIs. The information provided in this review will be of interest to researchers, clinicians, and patients seeking to optimize their UTI prevention and treatment strategies.

2. Pathogenesis of urinary tract infections

2.1. Overview of urinary tract infections-causing pathogens

The majority of UTIs are caused by uropathogenic *E. coli* (UPEC), which can colonize and invade the urinary tract epithelium, leading to inflammation and tissue damage¹. Other common UTI-causing pathogens include *Klebsiella pneumoniae*, *Proteus mirabilis*, and *Enterococcus faecalis*². The virulence factors of these pathogens, including adhesins, toxins, and iron-acquisition systems, are critical for colonization, invasion, and persistence in the urinary tract^{2,4}.

Uropathogenic *E. coli* is the most common cause of UTIs, accounting for over 80% of community-acquired UTIs¹³. The UPEC strains are genetically diverse and can express various virulence factors, including pili, fimbriae, and adhesins, that allow them to attach to and invade host cells¹³. The UPEC also produce toxins and iron acquisition systems that enable them to persist and cause inflammation in the urinary tract^{4,13}. Several studies have identified specific UPEC virulence factors associated with increased UTI severity and recurrence, including the P fimbriae and S fimbriae^{2,4,13}.

Klebsiella pneumoniae is another common cause of UTIs, particularly in hospitalized patients and those with underlying medical conditions². The *K. pneumoniae* strains can produce a range of virulence factors, including adhesins, capsule polysaccharides, and iron-acquisition systems, that enable them to colonize and cause infections in the urinary tract¹⁴. *Proteus mirabilis* is a common cause of catheter-associated UTIs and is characterized by its ability to swarm across surfaces and form biofilms¹⁵. *Enterococcus faecalis* is a less common UTI pathogen associated with recurrent infections and resistance to

multiple antibiotics¹⁶. Understanding the virulence factors and pathogenic mechanisms of these UTI-causing pathogens is critical for developing effective prevention and treatment strategies, including probiotics.

2.2. Pathogenesis of urinary tract infections

Understanding the pathogenesis of UTIs is critical for the development of effective prevention and treatment strategies². Adhesion, colonization, and biofilm formation are important mechanisms by which pathogenic bacteria cause UTIs^{2,4}. Adhesion to the urinary tract epithelium is the first step in the pathogenesis of UTIs. Adhesion is mediated by adhesins on the bacterial surface, which bind to specific receptors on the urinary tract epithelial cells. Adhesins can be expressed on fimbriae, pili, or other surface structures, and environmental signals can regulate their expression. The initial adhesion of bacteria to the urinary tract epithelium is a critical step in the pathogenesis of UTIs, as it allows bacteria to evade the host immune response and establish a foothold in the urinary tract^{2,4}.

Once bacteria have adhered to the urinary tract epithelium, they can colonize the urinary tract and initiate an inflammatory response². The expression of virulence factors, including iron acquisition systems and adhesins, facilitates colonization⁴. Iron is an necessary nutrient for bacterial growth, and the urinary tract is a relatively iron-poor environment. Pathogenic bacteria express iron acquisition systems, including siderophores, which enable them to scavenge iron from the host^{2,4}. Adhesins are critical for bacterial colonization, allowing bacteria to attach to and invade host cells⁴. Bacterial colonization of the urinary tract can lead to tissue damage and inflammation, which can cause symptoms of UTIs, including dysuria and urinary frequency^{2,4}.

Biofilm formation is an important mechanism by which bacteria can persist in the urinary tract and resist antimicrobial therapy¹⁷. Biofilms are complex bacteria communities encased in a matrix of extracellular polymeric substances¹⁸. Biofilms can form on the surface of urinary catheters, stones, or damaged urinary tract tissue, and are resistant to antibiotics and the host immune response¹⁸. Biofilm formation is mediated by a range of virulence factors, including polysaccharide adhesins, and is regulated by environmental signals¹⁷. The formation of biofilms can lead to persistent infections and recurrent UTIs, making them a significant clinical challenge^{17,18}.

2.3. Antibiotic resistance and its implications on urinary tract infections

Antibiotic resistance is a significant global health challenge that has important implications for the treatment of urinary tract infections (UTIs)⁶. The emergence and spread of antibiotic-resistant bacteria have been driven by a range of factors, including the overuse and misuse of antibiotics, as well as the spread of resistance genes through horizontal gene transfer¹⁹. Antibiotic resistance

can make UTIs more difficult to treat, as bacteria become resistant to commonly used antibiotics¹⁹.

Resistance to antibiotics used to treat UTIs is a growing concern, as many of the bacteria that cause UTIs have developed resistance to multiple antibiotics^{6,19}. This has led to a significant increase in the use of broad-spectrum antibiotics, which can have serious side effects and contribute to the development of antibiotic resistance¹⁹. In addition, the overuse of antibiotics has been associated with the disruption of the gut microbiota, which can lead to several health problems, including the development of antibiotic-resistant infections²⁰.

The rise of antibiotic-resistant UTIs has significant clinical implications, as it can lead to treatment failure, prolonged hospitalization, and increased healthcare costs²⁰. Treatment options for antibiotic-resistant UTIs are limited and may include the use of combination therapy, higher doses of antibiotics, or the use of last-line antibiotics⁶. These options are associated with significant risks and side effects, and may contribute to developing further antibiotic resistance¹⁹. In addition, there is a need for alternative approaches to the prevention and treatment of UTIs that do not rely on antibiotics²⁰.

3. Probiotics for the prevention of urinary tract infections

3.1. Mechanisms of action

The mechanisms of action of probiotics in preventing UTIs are multifactorial and involve a range of host and bacterial factors²¹. Probiotics can compete with uropathogens for nutrients and adhesion sites, produce bacteriocins that inhibit the growth of pathogenic bacteria, and modulate the host immune response⁹. In addition, probiotics can restore the balance of the gut and vaginal microbiota, which can protect uropathogens⁹.

Probiotics are effective in preventing UTIs by inhibiting the adhesion and colonization of uropathogens in the urinary tract^{9,21}. Several studies have indicated that probiotics can interfere with the adhesion of uropathogenic *E. coli* (UPEC) to uroepithelial cells, which is a critical step in the development of UTIs²². Probiotics can also prevent the formation of biofilms by UPEC, which can increase their resistance to antibiotics and immune defenses²³. By inhibiting the adhesion and colonization of uropathogens, probiotics can reduce the risk of UTIs^{22,23}.

Probiotics can also modulate the host immune response, which plays an important role in preventing UTIs⁹. Probiotics can enhance the production of immunoglobulins, cytokines, and other immune factors involved in the defense against uropathogens⁹. In addition, probiotics can downregulate the production of pro-inflammatory cytokines, contributing to the development of UTIs²⁴. By modulating the host immune response, probiotics can provide protection against UTIs and reduce the severity of infections^{9,24}.

The restoration of the gut and vaginal microbiota by probiotics is another mechanism by which they can

prevent UTIs²⁵. Disruption of the gut and vaginal microbiota can lead to dysbiosis, which can increase the risk of UTIs²⁵. Probiotics can restore the balance of the gut and vaginal microbiota, which can provide protection against uropathogens²⁵. In addition, probiotics can produce lactic acid, which can decrease the pH of the urine and inhibit the growth of uropathogens^{24,25}. The restoration of the gut and vaginal microbiota by probiotics is a promising approach for the prevention of UTIs, as it targets the underlying causes of UTIs²⁵.

3.2. Clinical evidences

Clinical studies have demonstrated the efficacy of specific probiotic strains in reducing the incidence of UTIs⁹. *Lactobacillus crispatus* and *L. rhamnosus* have been the most widely studied strains for this purpose^{12,21}.

The mechanism by which probiotics prevent UTIs is multifactorial²⁶. Probiotics have been indicated to modulate the host immune response, maintain a low vaginal pH, and produce bacteriocins that inhibit the growth of uropathogens⁹. In addition, probiotics are able to compete with uropathogens for adhesion sites on uroepithelial cells, preventing colonization and subsequent infection²¹. While further study is necessary to comprehend the mechanisms of action fully, the clinical evidence suggests that probiotics significantly decrease the incidence of UTIs^{9,21,26}.

In a randomized, double-blind, placebo-controlled trial, the use of a probiotic mixture containing *Lactobacillus acidophilus*, *L. rhamnosus*, and *Streptococcus thermophilus* (*S. thermophilus*) reduced the incidence of UTIs in women with recurrent UTIs²⁷. In another study, daily intake of *Lactobacillus crispatus* CTV-05 reduced the risk of recurrent UTIs in premenopausal women²⁸. Similarly, the use of *L. rhamnosus* GR-1 and *Lactobacillus reuteri* RC-14 reduced the incidence of UTIs in postmenopausal women²⁹.

Overall, the clinical evidence strongly supports the use of probiotics in the prevention of UTIs^{9,21,26}. While further studies are needed to establish optimal dosages and formulations, probiotics have the potential to significantly reduce the burden of UTIs and limit the overuse of antibiotics in this context. It is important, however, to identify the specific strains and doses of probiotics that are most effective for UTI prevention, as not all probiotics are equally effective in this regard³⁰.

3.3. Potential probiotics for prevention of urinary tract infections

Several bacterial strains have been explored for their potential to prevent UTIs, with *Lactobacillus* species being the most commonly studied^{21,27}.

Lactobacillus is one of the most commonly studied probiotic strains for UTI prevention, and is effective in decreasing the incidence of UTIs in some studies²⁷. Other strains of probiotics that have been studied for their potential to prevent UTIs include *Bifidobacterium*, *Streptococcus*, and *Enterococcus*, among others^{31,32}. These

strains have been found to prevent the growth of uropathogenic bacteria, prevent biofilm formation, and stimulate immune responses that can help prevent UTIs³². *Lactobacillus crispatus* is a strain of *Lactobacillus* that is particularly effective in preventing UTIs¹⁰. Studies have found that women with a healthy vaginal microbiome, including high levels of *Lactobacillus crispatus*, are less likely to experience UTIs¹⁰. *Lactobacillus crispatus* has been indicated to inhibit the growth of uropathogenic bacteria and promote the growth of beneficial bacteria that can help prevent UTIs¹⁰.

Another promising bacterial strain for UTI prevention is *E. coli* Nissle 1917 (EcN)³³. This strain has been extensively studied and has been shown to have a range of beneficial effects on the host immune system, including modulation of cytokine production, promotion of mucosal barrier function, and enhancement of innate and adaptive immune responses. In addition, EcN has been indicated to effectively inhibit uropathogenic *E. coli* through the secretion of microcins, which are small antimicrobial peptides that specifically target and kill related strains³³.

Other bacterial strains that have indicated potential for UTI prevention include *Bifidobacterium* species, which are commonly used in probiotic supplements for digestive health, and *S. thermophilus*, a commonly used yogurt starter culture³⁴. *Bifidobacterium* species have been indicated to decrease the risk of UTIs in postmenopausal women, and *S. thermophilus* has been indicated to inhibit the adhesion of uropathogenic *E. coli* to bladder cells. These strains, along with others such as *Enterococcus faecalis* and *Propionibacterium freudenreichii*, represent promising candidates for further investigation in the prevention of UTIs³⁴.

In addition to these specific probiotic strains, multi-strain probiotic supplements have also been studied for their potential to prevent UTIs¹⁰. These supplements typically contain a combination of *Lactobacillus* and *Bifidobacterium* strains, as well as other beneficial bacteria. Studies have found that multi-strain probiotics can be effective in reducing the incidence of UTIs in women with a history of recurrent UTIs¹⁰.

4. Probiotics for the treatment of urinary tract infections

4.1. Mechanisms of action

The mechanisms of action of probiotics in treating UTIs include the production of antibacterial compounds, competitive inhibition, and immunomodulation^{8,9}. Probiotics have been indicated to produce antibacterial compounds, such as organic acids and bacteriocins, which can inhibit the growth of uropathogens³⁵. *Lactobacillus crispatus* has been found to produce hydrogen peroxide, which can kill uropathogenic bacteria. *Lactobacillus acidophilus* and *L. rhamnosus* have been indicated to produce bacteriocins that can inhibit the growth of uropathogenic bacteria^{8,10}. Probiotics can also compete with uropathogens for adhesion to uroepithelial cells and

thereby prevent their colonization. *Lactobacilli* and *Bifidobacteria* can also acidify the urine, which can reduce the risk of UTI^{8,34}.

In addition to producing antibacterial compounds and competitive inhibition, probiotics can also modulate the immune response³⁶. Probiotics can increase the production of immunoglobulins, such as IgA, which can bind to uropathogens and prevent their adhesion to uroepithelial cells³⁶. Probiotics can also activate macrophages, natural killer cells, and neutrophils, which can kill uropathogens³⁷. Furthermore, probiotics can modulate the balance of T-helper cells, increasing the number of T-helper 1 cells, which produce interferon-gamma, a cytokine that can kill uropathogens³⁷.

Several clinical studies have investigated the use of probiotics in treating UTIs⁷⁻¹⁰. A randomized controlled trial found that a probiotic containing *Lactobacillus crispatus* reduced the recurrence of UTIs in women²⁸. Another study found that a probiotic containing *L. rhamnosus* and *Lactobacillus reuteri* reduced the incidence of UTIs in premenopausal women. In addition, a meta-analysis of 10 randomized controlled trials found that probiotics were effective in preventing UTIs¹⁰.

While the use of probiotics as an alternative therapy for UTIs is promising, there are still several challenges that need to be addressed. The optimal probiotic strain, dose, and duration of therapy need to be determined. In addition, the safety and efficacy of probiotics need to be established in larger, randomized, controlled trials. Overall, the use of probiotics as a potential alternative to antibiotics for the treatment of UTIs warrants further investigation⁶⁻¹⁰.

4.2. Clinical evidences

Probiotics are emerging as a promising alternative to antibiotics in the prevention and treatment of UTIs⁶. While the mechanisms by which probiotics exert their beneficial effects are still being elucidated, several clinical studies have provided evidence supporting their use in UTI treatment⁶.

In a randomized, double-blind, placebo-controlled study, female patients with recurrent UTIs were given *Lactobacillus crispatus* CTV-05, a probiotic strain isolated from the vagina³⁸. The study found that the probiotic group had a significantly lower incidence of UTIs compared to the placebo group³⁸. Another clinical trial investigated the efficacy of the probiotic combination of *L. rhamnosus* GR-1 and *Lactobacillus reuteri* RC-14 in the treatment of acute UTIs³⁹. The probiotic group showed a higher rate of resolution of symptoms and bacterial eradication compared to the placebo group³⁹.

A study by Beerepoot et al. showed that daily oral administration of *L. rhamnosus* GR-1 and *Lactobacillus reuteri* RC-14 in women with recurrent UTIs led to a decrease in the incidence of UTIs compared to placebo. This study involved a randomized, double-blind, placebo-controlled trial of 252 women, and the results showed that the use of probiotics reduced the risk of UTIs by approximately 50%⁴⁰.

Another clinical study by Stapleton et al. investigated the use of oral *Lactobacillus crispatus* in premenopausal women with a history of recurrent UTIs⁴¹. The results showed a significant reduction in the recurrence rate of UTIs in the probiotic group compared to the placebo group⁴¹. The authors concluded that oral probiotics are a safe and effective alternative for the prevention of UTIs in women⁴¹.

A recent systematic review and meta-analysis by Gao et al. also supported the use of probiotics for the treatment of UTIs. This study evaluated the efficacy of probiotics for the treatment of UTIs and included 11 randomized controlled trials with a total of 1,507 patients⁴². The results indicated that the use of probiotics was associated with a significant reduction in the incidence of recurrent UTIs⁴².

In addition to the studies above, a recent study by Khalesi et al. found that oral probiotics were effective in reducing the recurrence of UTIs in women with a history of UTIs⁴³. This randomized controlled trial included 120 women and found that the use of *Lactobacillus acidophilus* and *Bifidobacterium lactis* reduced the incidence of UTIs by 45.7%⁴³.

Another study by Czaja et al. evaluated the use of a vaginal probiotic containing *Lactobacillus crispatus* in women with recurrent UTIs⁴⁴. The results showed that the probiotic group had a lower incidence of UTIs compared to the control group. The authors suggested that the use of vaginal probiotics may be an effective way to prevent UTIs in women⁴⁴.

Furthermore, in vitro studies have shed light on the mechanisms by which probiotics prevent and treat UTIs^{6,8}. Probiotics have been indicated to compete with uropathogens for adherence to uroepithelial cells, effectively preventing the pathogens from colonizing the urinary tract. Probiotics can also modulate the host immune response, which plays a key role in the pathogenesis of UTIs^{8,34}. For example, some probiotic strains have been indicated to decrease the expression of cytokines and chemokines that recruit immune cells to the urinary tract, thereby enhancing the host's ability to fight off infections³⁴.

While the clinical evidence supporting the use of probiotics in UTI treatment is promising, further studies are needed to elucidate the optimal dosing and strain selection^{7,8}. Additionally, the use of probiotics as a stand-alone treatment for UTIs may not be effective in all cases, and they may need to be used in combination with antibiotics or other treatments^{7,8}. Nonetheless, the use of probiotics as a complementary or alternative approach to UTI treatment holds great promise, particularly in light of the rising rates of antibiotic resistance⁷⁻¹⁰.

4.3. Potential probiotic strains for treatment of urinary tract infections

Many strains of probiotics have been investigated for their potential to treat UTIs⁷⁻¹⁰. One strain that has indicated promise in clinical studies is *Lactobacillus crispatus*⁸. In a study of premenopausal women with

recurrent UTIs, daily oral intake of a *L. crispatus* probiotic was associated with a significant reduction in the frequency of UTIs^{8,10}. Another strain that has been studied is *Lactobacillus fermentum*. In a randomized controlled trial of postmenopausal women with recurrent UTIs, daily intake of a *L. fermentum* probiotic was associated with a significant decrease in the incidence of UTIs¹⁰. However, more research is needed to determine the optimal dose and duration of treatment with these strains.

Another promising strain for UTI treatment is *L. rhamnosus* GR-1³⁹. In a double-blind, placebo-controlled trial of women with acute UTIs, treatment with a combination of *L. rhamnosus* GR-1 and *Lactobacillus reuteri* RC-14 was associated with a higher rate of clinical cure and a lower rate of recurrence compared to placebo³⁹. Similarly, a study of pregnant women found that treatment with *L. rhamnosus* GR-1 and *L. reuteri* RC-14 was associated with a lower incidence of UTIs compared to placebo⁴⁰.

Bifidobacterium bifidum is another probiotic strain that has indicated potential for UTI treatment^{10,31,32}. In a study of premenopausal women with recurrent UTIs, daily intake of a probiotic containing *B. bifidum* was associated with a lower incidence of UTIs compared to placebo³². Additionally, a randomized controlled trial of women with acute uncomplicated cystitis found that treatment with a combination of *B. bifidum* and *L. acidophilus* was associated with a higher rate of clinical cure than a placebo^{31,32}.

Other probiotic strains that have been investigated for their potential to treat UTIs include *S. thermophilus*, *Enterococcus faecalis*, and *Bifidobacterium lactis*³⁴. However, more research is needed to determine their efficacy in treating UTIs.

5. Probiotics for the prevention and treatment of recurrent urinary tract infections

5.1. Definition and epidemiology

Recurrent urinary tract infections (rUTIs) are defined as two or more UTIs within six months or three or more UTIs within one year⁴⁵. The rUTIs affect a substantial number of women and are a significant public health concern, leading to substantial morbidity and healthcare costs⁴⁵. The incidence of rUTIs in young, healthy women is estimated to be around 25%, with up to 50% of these women experiencing additional UTIs⁴⁶. In postmenopausal women, the incidence of rUTIs increases, with up to 50% of women experiencing rUTIs⁴⁶.

Recurrent UTIs are a multifactorial condition that is often associated with host factors, such as age, gender, genetics, and underlying medical conditions, as well as bacterial virulence factors⁴⁵. Among the bacterial virulence factors that contribute to rUTIs are the formation of biofilms, the expression of adhesive structures, and the acquisition of antibiotic resistance⁴⁷. Biofilm formation by uropathogenic bacteria may play a particularly important role in the pathogenesis of rUTIs⁴⁷. The biofilm matrix provides protection against antibiotics and the host immune system, allowing the bacteria to persist in the

urinary tract and cause recurrent infections⁴⁷.

Recurrent UTIs are typically treated with antibiotics, but the emergence of antibiotic-resistant strains often limits this approach^{46,47}. Moreover, repeated courses of antibiotics can lead to alterations in the urinary microbiome, potentially increasing the risk of rUTIs^{46,47}. Alternative approaches to the prevention and treatment of rUTIs are therefore needed. Probiotics are a promising intervention for preventing and treating rUTIs, as they can restore the normal urogenital microbiota and inhibit the growth and virulence of uropathogenic bacteria⁴⁵.

5.2. Mechanisms of action

The mechanisms by which probiotics exert their effects in preventing and treating rUTIs are not fully understood. However, they involve several factors, including the microbiota modulation, the production of antibacterial compounds, and the strengthening of the epithelial barrier³⁸.

One of the key mechanisms by which probiotics may prevent rUTIs is by modulating the gut and vaginal microbiota⁴⁸. Dysbiosis in the vaginal microbiota, characterized by a reduction in *Lactobacillus* species and an overgrowth of pathogenic bacteria, has been associated with an increased risk of UTIs. Probiotics can help restore the normal vaginal microbiota and prevent the overgrowth of pathogenic bacteria⁴⁸. The use of probiotics may also help prevent the spread of uropathogens from the gut to the urinary tract, as some probiotic strains have been indicated to colonize the gut and vagina and compete with uropathogenic bacteria for resources⁴⁸.

Another mechanism by which probiotics may prevent rUTIs is through the production of antibacterial compounds, such as organic acids and bacteriocins⁴⁹. These compounds can inhibit the growth of uropathogenic bacteria and prevent them from colonizing the urinary tract⁴⁹. Probiotic strains have also been indicated to induce the production of host antimicrobial peptides, such as defensins, which can enhance the innate immune response to infection and help prevent the recurrence of UTIs⁴⁹.

In addition to their preventative effects, probiotics may also effectively treat rUTIs. Several studies have indicated that the use of probiotics as an adjunct to antibiotics can improve the clinical outcomes of UTIs, including reducing the incidence of recurrent infections³⁸. This may be due in part to the ability of probiotics to enhance the efficacy of antibiotics by reducing the potential for antibiotic resistance and promoting the clearance of uropathogens. Probiotics may also enhance the immune response to infection, and reduce the risk of complications associated with rUTIs, such as pyelonephritis and sepsis^{38,48}.

5.3. Clinical evidences

Clinical evidence supporting the use of probiotics for rUTIs is steadily increasing^{45,46}. A meta-analysis of randomized controlled trials (RCTs) assessing the effectiveness of probiotics for preventing rUTIs found that

probiotics significantly reduced the risk of rUTIs, compared to placebo or no treatment³⁸. Several RCTs have also reported a decrease in the number of UTIs and a decrease in antibiotic use in participants who took probiotics compared to those who did not. However, the optimal dose, frequency, and duration of probiotic supplementation are not yet well established, and more research is needed to address these issues^{38,45,46}.

The mechanisms of action by which probiotics prevent rUTIs are not completely understood, but they likely involve several factors⁴⁷. Probiotics may improve the composition and function of the vaginal and gut microbiota, which can affect the vaginal and urinary microbiota⁴⁷. Additionally, probiotics may produce antimicrobial substances that inhibit the growth of uropathogenic bacteria, or they may compete with uropathogens for nutrients and adhesion sites in the urinary tract⁴⁵. Probiotics may also modulate the host immune response to prevent colonization by uropathogens⁴⁷.

5.4. Potential probiotic strains for recurrent urinary tract infections

As described earlier, recurrent UTIs can be challenging to treat with antibiotics, as the bacteria can develop resistance and the immune system may be unable to clear the infection³⁸. Probiotics may offer a promising alternative or adjunct therapy, as they can help restore the natural balance of microorganisms in the urinary tract and enhance the body's defenses against infection^{38,45}. There are several potential probiotic strains that have been studied for their effectiveness in preventing and treating recurrent UTIs^{38,47,48}.

One potential probiotic strain is *Lactobacillus crispatus* (*L. crispatus*), which is a common inhabitant of the healthy vaginal microbiota and has been indicated to be associated with a lower risk of UTIs⁴⁸. Studies have indicated that oral or intravaginal administration of *L. crispatus* can reduce the incidence and recurrence of UTIs, as well as decrease the severity of symptoms⁴⁸. This strain may work by promoting the growth of beneficial bacteria in the urinary tract, stimulating the immune system, and producing antimicrobial compounds⁴⁸.

Another potential probiotic strain for recurrent UTIs is *Lactobacillus rhamnosus GR-1*, which has been indicated to be effective in preventing and treating various types of infections^{39,40}. This strain may work by adhering to the epithelial cells of the urinary tract and preventing the attachment and growth of pathogenic bacteria, as well as modulating the immune response and producing antimicrobial substances. Studies have indicated that oral administration of *L. rhamnosus GR-1* can significantly reduce the incidence and severity of UTIs^{39,40}.

Bifidobacterium longum has also been studied as a potential probiotic strain for recurrent UTIs, as it is a common inhabitant of the gut microbiota and has been indicated to have immunomodulatory and antimicrobial properties^{31,32}. Studies have indicated that oral

administration of *B. longum* can significantly reduce the incidence and severity of UTIs, as well as increase the levels of beneficial bacteria in the urinary tract^{31,32}. This strain may work by modulating the host immune response and producing bacteriocins and other antimicrobial compounds^{31,32}.

Finally, *S. thermophilus* is another potential probiotic strain for recurrent UTIs, as it has been indicated to have immunomodulatory and antimicrobial properties. Studies have shown that oral administration of *S. thermophilus* can significantly reduce the incidence and severity of UTIs, as well as increase the levels of beneficial bacteria in the urinary tract³⁴. This strain may work by modulating the host immune response and producing bacteriocins and other antimicrobial compounds³⁴.

6. Safety and potential side effects of probiotics

6.1. Safety of probiotics

Probiotics are live microorganisms that provide health benefits when consumed in adequate amounts⁹. While probiotics have gained widespread attention for their potential to prevent and treat UTIs, their safety profile is a crucial consideration²⁸. The safety of probiotics is generally considered to be favorable, although it is important to assess potential risks associated with their use⁵⁰.

Studies have suggested that probiotics are associated with a low risk of adverse effects, with most adverse events being mild and self-limiting^{9,10}. The majority of adverse events reported with probiotic use are related to gastrointestinal symptoms such as flatulence, bloating, and abdominal discomfort. However, these symptoms typically resolve within a few days and are not considered serious⁵⁰.

The safety of probiotics is also affected by the type of strain used, as different strains can have different effects on the body⁵⁰. Some probiotic strains have been associated with more severe adverse events, particularly in individuals with compromised immune systems⁵⁰. For this reason, it is important to carefully select the strain of probiotic used, as well as to assess the risk of potential adverse events in different populations, such as immunocompromised individuals or infants^{50,51}.

The use of probiotics in the prevention and treatment of UTIs has been indicated to be generally safe, with a low risk of adverse events. In a systematic review and meta-analysis of randomized controlled trials, probiotics were found to be generally safe and well-tolerated, with no serious adverse events reported⁵¹. Another systematic review of studies examining the use of probiotics for the prevention of UTIs also reported a low incidence of adverse events associated with probiotic use⁵².

6.2. Side effects and risk factors associated with probiotics

Although generally considered safe, probiotics may be

associated with certain side effects and risks, particularly in individuals with compromised immune systems or underlying medical conditions⁵³.

The most common side effects associated with probiotic use are gastrointestinal disturbances, such as bloating, gas, and diarrhea⁵⁴. These side effects are generally mild and self-limited and tend to resolve with continued use of the probiotic. However, in some cases, particularly in individuals with weakened immune systems, probiotic use may lead to serious infections, such as sepsis or endocarditis⁵⁴.

Another potential risk associated with probiotic use is the risk of antibiotic resistance⁶. Some studies have suggested that certain strains of probiotics may acquire resistance genes from other bacteria in the gut, potentially leading to the development of antibiotic-resistant strains⁶. This is particularly concerning in the context of recurrent UTIs, often treated with antibiotics⁶.

In addition to these risks, there have also been reports of probiotic-induced infections, particularly in individuals with compromised immune systems⁵³. For example, a study described a patient with acute pancreatitis who developed sepsis after taking a probiotic supplement containing *Lactobacillus rhamnosus GG*⁵³. Although such cases are rare, they underscore the importance of caution when using probiotics, particularly in vulnerable populations.

It is worth reiterating twice that the safety of probiotics may vary depending on the specific strain and formulation used⁵⁵. For example, a study of a probiotic supplement containing *Lactobacillus casei* found that it was associated with an increased risk of acute pancreatitis in a small number of patients⁵⁵. Therefore, it is important to carefully consider the risks and benefits of individual probiotic supplements before use, particularly in individuals with underlying medical conditions or compromised immune systems.

6.3. Strategies for ensuring probiotic safety and efficacy

The use of probiotics is generally considered safe, but there are still concerns about their safety and efficacy, particularly in vulnerable populations such as critically ill patients, infants, and the elderly⁵⁰. Therefore, several strategies have been proposed to ensure the safety and efficacy of probiotics, such as using probiotic strains that have been extensively studied and have a good safety record, and monitoring for adverse effects during use.

One strategy for ensuring probiotic safety is to use well-characterized probiotic strains that have been extensively studied in human trials⁵⁰. For example, the strain *Lactobacillus rhamnosus GG* has been used in many clinical trials and has a long safety record, making it a reliable choice for probiotic supplementation⁵³. Other strains, such as *Lactobacillus acidophilus* and *Bifidobacterium bifidum*, have also been extensively studied and are considered safe for use in humans^{31,32}.

Another strategy for ensuring probiotic safety is to monitor for adverse effects during use⁵⁶. Although

probiotics are generally well-tolerated, adverse effects such as gastrointestinal upset, allergic reactions, and infections have been reported in some cases⁵⁶. Therefore, monitoring for adverse effects during probiotic supplementation is important to identify and manage any potential safety concerns.

Prebiotics can also be used to improve the safety and efficacy of probiotics⁵⁷. Prebiotics are non-digestible carbohydrates that selectively stimulate the growth and activity of beneficial bacteria in the gut, including probiotics⁵⁷. By providing a favorable environment for probiotic growth and activity, prebiotics can enhance the efficacy of probiotic supplementation and reduce the risk of adverse effects⁵⁷.

Formulation and delivery methods can also influence the safety and efficacy of probiotics⁵⁸. Different formulations, such as capsules, tablets, and powders, may have different effects on the survival and viability of probiotic strains, as well as their release and colonization in the gut⁵⁸. Therefore, choosing the appropriate formulation and delivery method is important for ensuring the safety and efficacy of probiotics.

Finally, regulatory oversight is important for ensuring the safety and efficacy of probiotics. In some countries, such as the United States and Canada, probiotics are considered a food supplement and are not subject to the same regulatory oversight as drugs. However, other countries, such as Australia and the European Union, regulate probiotics as therapeutic goods and require manufacturers to provide evidence of safety and efficacy before being sold to the public. This regulatory oversight can help ensure that probiotics are safe and effective for human use⁵⁹.

7. Future directions and challenges

7.1. Future research on probiotics and urinary tract infections

Current research on probiotics and UTIs is rapidly expanding, and many promising avenues exist for future research⁹. One area of interest is the identification of optimal probiotic strains, dosages, and formulations for UTI prevention and treatment. To this end, researchers are investigating various strains of *Lactobacillus*, *Bifidobacterium*, and other bacteria to determine which ones are most effective in combating UTIs^{31,32,52}.

Another area of research is the development of probiotic formulations that can withstand harsh conditions in the urinary tract, such as acidic urine and bacterial competition. Researchers are exploring various technologies, such as microencapsulation, to enhance the survival and effectiveness of probiotics in the urinary tract⁶⁻¹⁰.

In addition, researchers are investigating the mechanisms by which probiotics exert their beneficial effects on the urinary tract. This includes studying the interactions between probiotics and the host immune system, as well as the ways in which probiotics modulate the urinary microbiome⁶⁻¹⁰.

7.2. Challenges and limitations of probiotics in urinary tract infections

There are several challenges and limitations to the use of probiotics for UTIs. One of the most significant challenges is the lack of standardization in probiotic products, with significant variability in the type and quantity of strains present in different products. This variability can make it difficult to compare results between studies or to determine optimal dosing⁹.

Another challenge is the potential for probiotics to interact with other medications or conditions. For example, some strains of *Lactobacillus* have been associated with increased rates of fungal infections in immunocompromised individuals. Similarly, probiotics may interfere with the efficacy of antibiotics or other medications, leading to suboptimal treatment outcomes³¹.

In addition, there is limited knowledge about the optimal strains and dosing of probiotics for UTI prevention and treatment, with some studies showing conflicting results. Furthermore, the effectiveness of probiotics may vary depending on the patient population, with some studies showing limited benefit in high-risk groups such as those with recurrent UTIs or catheter-associated infections⁵⁸.

7.3. Improvement in technology and administration of probiotics

While there have been some promising results with the use of probiotics for UTIs, there are also many challenges and limitations to their use. One potential area for improvement in probiotic technology is the development of more effective and targeted formulations⁵⁸.

A promising area of research is the use of engineered probiotics, which have been genetically modified to enhance their efficacy and targeting. For example, a study has indicated that the use of engineered *Lactobacillus crispatus* strains expressing D-mannose-binding lectin could prevent uropathogenic *E. coli* (UPEC) from adhering to the bladder wall. This approach could potentially be used to create probiotics that are more effective at preventing UTIs by specifically targeting the pathogens responsible for these infections⁶⁰.

Another potential area for improvement is the development of probiotic delivery systems that can better survive the harsh conditions of the urinary tract⁶¹. For example, one study has indicated that a probiotic formulation of *Lactobacillus crispatus* in alginate-chitosan microcapsules could survive the acidic conditions of the stomach and colon, as well as the bactericidal effects of urine. This approach could potentially be used to develop probiotics that can reach the urinary tract and colonize the bladder⁶¹.

In addition, there is a need for a better understanding of the mechanisms of action of probiotics in UTIs, and the development of more effective methods for selecting and characterizing probiotic strains⁶². For example, the use of

high-throughput sequencing and metabolomics could help to identify the specific mechanisms by which probiotics prevent and treat UTIs, as well as the specific strains and metabolites that are most effective. This could help to improve the efficacy and safety of probiotics for UTIs, and pave the way for the development of more targeted and effective probiotic therapies⁶².

8. Conclusion

It is clear from the literature that probiotics have the potential to be a safe and effective alternative or complementary therapy for preventing and treating recurrent UTIs.

The implications of probiotics in clinical practice and public health are significant. The use of probiotics in preventing and treating UTIs can potentially reduce the overuse of antibiotics, which has been a major factor in the development of antibiotic resistance. Additionally, probiotics can prevent the occurrence of UTIs in vulnerable populations, such as women and the elderly. The use of probiotics can also potentially improve the quality of life for individuals with recurrent UTIs.

Future research on probiotics and UTIs should focus on identifying optimal strains, dosages, and delivery methods. Additional clinical trials are needed to evaluate the safety and efficacy of probiotics in different populations and to identify potential interactions with other medications. Studies are also needed to explore the use of probiotics in combination with antibiotics and to evaluate the long-term effects of probiotic use.

In conclusion, the use of probiotics in prevention and treatment of UTIs represents a promising area of research and clinical practice. While there are challenges and limitations to their use, the potential benefits are significant. Continued research and development of probiotic technology and administration can potentially improve the safety and efficacy of probiotics in prevention and treatment of recurrent UTIs. Overall, the potential of probiotics to combat UTIs is a promising avenue for improving public health and reducing the burden of antibiotic resistance.

Declarations

Competing interests

The authors declare that they have no conflict of interest.

Authors' contribution

All authors were involved in data collection, design of the article, interpretation of results, review, and manuscript preparation.

Funding

The authors received no financial support for the publication of this article.

Availability of data and materials

The authors are ready to prepare all collected data of this study upon the reasonable requests.

Ethical considerations

The authors checked for plagiarism and consented to the publishing of the article. The authors have also checked the article for data fabrication, double publication, and redundancy.

Acknowledgments

We would like to express our gratitude to the University of Sistan and Baluchestan for providing financial support for this review. This support was critical in allowing us to conduct a comprehensive literature review on the use of probiotics for urinary tract infections. The funds provided enabled us to access a wide range of research articles and data sources, which were essential in identifying the latest developments and emerging trends in this field.

References

1. Salahshoori Niaei F, Farah Taj Navab A. Effects of *Valeriana officinalis* and ciprofloxacin on kidney histopathology in rats pyelonephritis by pseudomonas *aeruginosa*. Rev Environ Sci Biotechnol. 2022; 1(1): 23-27. Available at: https://rbes.rovedar.com/article_160898.html
2. Foxman B. Urinary tract infection syndromes: Occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014; 28(1), 1–13. DOI: [10.1016/j.idc.2013.09.003](https://doi.org/10.1016/j.idc.2013.09.003)
3. Valiquette L. Urinary tract infections in women. Can J Urol. 2001; 8(Supple 1): 6-12. Available at: <https://pubmed.ncbi.nlm.nih.gov/11442991/>
4. Flores-Mireles AL, Walker JN, Caparon M, and Hultgren SJ. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol, 2015; 13(5): 269-284. DOI: [10.1038/nrmicro3432](https://doi.org/10.1038/nrmicro3432)
5. Mego M, Holec V, Drgona L, Hainova K, Ciernikova S, and Zajac V. Probiotic bacteria in cancer patients undergoing chemotherapy and radiation therapy. Complement Ther Med. 2013; 21(6): 712-723. DOI: [10.1016/j.ctim.2013.08.018](https://doi.org/10.1016/j.ctim.2013.08.018)
6. Afolayan AO, Adetoye A, and Ayeni FA. Beneficial microbes: Roles in the era of antimicrobial resistance. In Kumar Y, editor. Antimicrobial resistance-A global threat. 2018. Available at: <https://www.intechopen.com/chapters/63124>
7. Jones-Freeman B, Chonwerawong M, Marcelino VR, Deshpande AV, Forster SC, and Starkey MR. The microbiome and host mucosal interactions in urinary tract diseases. Mucosal Immunol. 2021; 14(4): 779-792. DOI: [10.1038/s41385-020-00372-5](https://doi.org/10.1038/s41385-020-00372-5)
8. Martín R, and Langella P. Emerging health concepts in the probiotics field: Streamlining the definitions. Front microb. 2019; 10: 1047. DOI: [10.3389/fmicb.2019.01047](https://doi.org/10.3389/fmicb.2019.01047)
9. Sánchez B, Delgado S, Blanco-Míguez A, Lourenço A, Gueimonde M, and Margolles A. Probiotics, gut microbiota, and their influence on host health and disease. Mol Nutr Food Res. 2017; 61(1): 1600240. DOI: [10.1002/mnfr.201600240](https://doi.org/10.1002/mnfr.201600240)
10. Ng QX, Peters C, Venkatanarayanan N, Goh YY, Ho CY, and Yeo WS. Use of *Lactobacillus* spp. to prevent recurrent urinary tract infections in females. Med Hypotheses. 2018; 114: 49-54. DOI: [10.1016/j.mehy.2018.03.001](https://doi.org/10.1016/j.mehy.2018.03.001)
11. Heidari F, Abbaszadeh S, and Mirak SE. Evaluation effect of combination probiotics and antibiotics in the prevention of recurrent urinary tract infection (UTI) in women. Biomed Pharmacol J. 2017; 10(2): 691-698. DOI: [10.13005/bpj/1157](https://doi.org/10.13005/bpj/1157)
12. Mantegazza C, Molinari P, D'Auria E, Sonnino M, Morelli L, and Zuccotti GV. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on *Lactobacillus rhamnosus* GG during and after antibiotic treatment. Pharmacol Res. 2018; 128: 63-72. DOI: [10.1016/j.phrs.2017.08.001](https://doi.org/10.1016/j.phrs.2017.08.001)
13. Kim WB, Cho KH, Lee SW, Yang HJ, Yun JH, Lee KW, et al. Recent antimicrobial susceptibilities for uropathogenic *Escherichia coli* in patients with community acquired urinary tract infections: A multicenter study. Urogenit Tract Infect. 2017; 12(1): 28-34. DOI: [10.14777/uti.2017.12.1.28](https://doi.org/10.14777/uti.2017.12.1.28)
14. Clegg S, and Murphy CN. Epidemiology and virulence of *Klebsiella pneumoniae*. Microbiol Spectr. 2017; 4(1): 435-457. DOI: [10.1128/microbiolspec.uti-0005-2012](https://doi.org/10.1128/microbiolspec.uti-0005-2012)
15. Fusco A, Coretti L, Savio V, Buommino E, Lembo F, and Donnarumma G. Biofilm formation and immunomodulatory activity of *Proteus mirabilis* clinically isolated strains. Int J Mol Sci. 2017; 18(2): 414. DOI: [10.3390/ijms18020414](https://doi.org/10.3390/ijms18020414)
16. Silva A, Costa E, Freitas A, and Almeida A. Revisiting the frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections. Antibiotics. 2022; 11(6): 768. DOI: [10.3390/antibiotics11060768](https://doi.org/10.3390/antibiotics11060768)
17. Ciofu O, and Tolker-Nielsen T. Tolerance and resistance of *Pseudomonas aeruginosa* biofilms to antimicrobial agents—how *P. aeruginosa* can escape antibiotics. Front microb. 2019; 10: 913. DOI: [10.3389/fmicb.2019.00913](https://doi.org/10.3389/fmicb.2019.00913)
18. Mahto KU, Vandana, Priyadarshane M, Samantaray DP, and Das S. Bacterial biofilm and extracellular polymeric substances in the treatment of environmental pollutants: Beyond the protective role in survivability. J Clean Prod. 2022; 379: 134759. DOI: [10.1016/j.jclepro.2022.134759](https://doi.org/10.1016/j.jclepro.2022.134759)
19. Serwecińska L. Antimicrobials and antibiotic-resistant bacteria: A risk to the environment and to public health. Water. 2020; 12(12): 3313. DOI: [10.3390/w12123313](https://doi.org/10.3390/w12123313)
20. Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, and Cohen H. Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol. 2020; 10: 572912. DOI: [10.3389/fcimb.2020.572912](https://doi.org/10.3389/fcimb.2020.572912)
21. Hashempour-Baltork F, Sheikh M, Eskandarzadeh S, Tarlak F, Tripathi AD, Khosravi-Darani K, et al. The Effect of probiotics on various diseases and their therapeutic role: An update review. J Pure Appl Microbiol. 2021; 15(3): 1042-1059. DOI: [10.22207/JPAM.15.3.17](https://doi.org/10.22207/JPAM.15.3.17)
22. Ghane M, Babaekhou L, and Ketabi SS. Antibiofilm activity of kefir probiotic lactobacilli against uropathogenic *Escherichia coli* (UPEC). Avicenna J Med Biotechnol. 2020; 12(4): 221-229. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502162/>
23. Gümüş D, Yüsek FK, Bilgin M, Camadan FD, and Küçüker MA. *In Vitro* effects of various probiotic products on growth and biofilm formation of clinical UPEC strains. Acta Biol Marisensis. 2020; 3(1): 5-14. DOI: [10.2478/abmj-2020-0001](https://doi.org/10.2478/abmj-2020-0001)
24. Dargahi N, Matsoukas J, and Apostolopoulos V. *Streptococcus thermophilus* ST285 alters pro-inflammatory to anti-inflammatory cytokine secretion against multiple sclerosis peptide in mice. Brain sci. 2020; 10(2): 126. DOI: [10.3390/brainsci10020126](https://doi.org/10.3390/brainsci10020126)
25. Barrientos-Durán A, Fuentes-López A, de Salazar A, Plaza-Díaz J, and García F. Reviewing the composition of vaginal microbiota: Inclusion of nutrition and probiotic factors in the maintenance of eubiosis. Nutrients. 2020; 12(2): 419. DOI: [10.3390/nu12020419](https://doi.org/10.3390/nu12020419)
26. Koradia P, Kapadia S, Trivedi Y, Chanchu G, and Harper A. Probiotic and cranberry supplementation for preventing recurrent uncomplicated urinary tract infections in premenopausal women: A controlled pilot study. Expert Rev Anti Infect Ther. 2019; 17(9): 733-740. DOI: [10.1080/14787210.2019.1664287](https://doi.org/10.1080/14787210.2019.1664287)
27. Beyitler I, and Kavukcu S. Probiotics for prophylaxis and treatment of urinary tract infections in children. Iran J Pediatr. 2017; 27(2): e7695. DOI: [10.5812/ijp.7695](https://doi.org/10.5812/ijp.7695)
28. Akgül T, and Karakan T. The role of probiotics in women with recurrent urinary tract infections. Turk J Urol. 2018; 44(5): 377-383. DOI: [10.5152/2Ftud.2018.48742](https://doi.org/10.5152/2Ftud.2018.48742)
29. Saha UB, and Saroj SD. Lactic acid bacteria: Prominent player in the fight against human pathogens. Expert Rev Anti Infect Ther. 2022; 20(11): 1435-1453. DOI: [10.1080/14787210.2022.2128765](https://doi.org/10.1080/14787210.2022.2128765)
30. Babazadeh D, Vahdatpour T, Nikpiran H, Jafargholipour MA, and Vahdatpour S. Effects of probiotic, prebiotic and synbiotic intake on blood enzymes and performance of Japanese quails (*Coturnix japonica*). Indian J Anim Sci. 2011; 81(8): 870-874.
31. Mirzaei A, Razavi SA, Babazadeh D, Laven R, and Saeed M. Roles of Probiotics in Farm Animals: A Review. FAHN. 2022; 1(1): 17-25. Available

- at: https://fahn.rovedar.com/article_160928_e7a5fc9842a2220112f64daeb52316ed.pdf
32. Sikorska H, and Smoragiewicz W. Role of probiotics in the prevention and treatment of meticillin-resistant *Staphylococcus aureus* infections. *Int J Antimicrob Agents*. 2013; 42(6): 475-481. DOI: [10.1016/j.ijantimicag.2013.08.003](https://doi.org/10.1016/j.ijantimicag.2013.08.003)
 33. Rodríguez-Nogales A, Algieri F, Garrido-Mesa J, Vezza T, Utrilla MP, Chueca N, et al. The administration of *Escherichia coli* Nissle 1917 ameliorates development of DSS-induced colitis in mice. *Front pharmacol*. 2018; 9: 468. DOI: [10.3389/fphar.2018.00468](https://doi.org/10.3389/fphar.2018.00468)
 34. Crittenden RG, Martinez NR, and Playne MJ. Synthesis and utilisation of folate by yoghurt starter cultures and probiotic bacteria. *Int J Food Microbiol*. 2003; 80(3): 217-222. DOI: [10.1016/s0168-1605\(02\)00170-8](https://doi.org/10.1016/s0168-1605(02)00170-8)
 35. Vahdatpour T, and Babazadeh D. The effects of Kefir rich in probiotic administration on serum enzymes and performance in male Japanese quails. *J Anim Plant Sci*. 2016; 26(1): 34-39. Available at: <https://www.thejaps.org.pk/docs/v-26-01/05.pdf>
 36. Mendonça FH, Santos SS, Faria ID, Gonçalves e Silva CR, Jorge AO, and Leão MV. Effects of probiotic bacteria on *Candida* presence and IgA anti-*Candida* in the oral cavity of elderly. *Braz Dent J*. 2012; 23: 534-538. DOI: [10.1590/s0103-64402012000500011](https://doi.org/10.1590/s0103-64402012000500011)
 37. Abraham SN, and Miao Y. The nature of immune responses to urinary tract infections. *Nat Rev Immunol*. 2015; 15(10): 655-663. DOI: [10.1038/nri3887](https://doi.org/10.1038/nri3887)
 38. Gupta V, Nag D, and Garg P. Recurrent urinary tract infections in women: How promising is the use of probiotics?. *Indian J Med Microbiol*. 2017; 35(3): 347-354. DOI: [10.4103/ijmm.ijmm.16.292](https://doi.org/10.4103/ijmm.ijmm.16.292)
 39. Petrova MI, Reid G, and Ter Haar JA. *Lactobacillus rhamnosus* GR-1, aka *Lactobacillus rhamnosus* GR-1: Past and future perspectives. *Trends Microbiol*. 2021; 29(8): 747-761. DOI: [10.1016/j.tim.2021.03.010](https://doi.org/10.1016/j.tim.2021.03.010)
 40. Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM, et al. *Lactobacilli* vs antibiotics to prevent urinary tract infections: A randomized, double-blind, noninferiority trial in postmenopausal women. *Arch Intern Med*. 2012; 172: 704-712. DOI: [10.1001/archinternmed.2012.777](https://doi.org/10.1001/archinternmed.2012.777)
 41. Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, et al. Randomized, placebo controlled Phase 2 trial of a *Lactobacillus crispatus* probiotic given intravaginally for the prevention of recurrent urinary tract infection. *Clin Infect Dis*. 2011; 52(10): 1212-1217. DOI: [10.1093/cid/cir183](https://doi.org/10.1093/cid/cir183)
 42. Gao J, Zhao L, Cheng Y, Lei W, Wang Y, Liu X, et al. Probiotics for the treatment of depression and its comorbidities: A systemic review. *Front Cell Infect Microbio*. 2023; 13: 1167116. DOI: [10.3389/fcimb.2023.1167116](https://doi.org/10.3389/fcimb.2023.1167116)
 43. Khalesi S, Johnson DW, Campbell K, Williams S, Fenning A, Saluja S, et al. Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: A systematic review and meta-analysis. *Eur J Nutr*. 2018; 57(6): 2037-2053. DOI: [10.1007/s00394-017-1568-y](https://doi.org/10.1007/s00394-017-1568-y)
 44. Czaja CA, Stapleton AE, Yarova-Yarovaya Y, and Stamm WE. Phase I trial of a *Lactobacillus crispatus* vaginal suppository for prevention of recurrent urinary tract infection in women. *Infect Dis Obstet Gynecol*. 2007; 2007: 35387. DOI: [10.1155/2007/35387](https://doi.org/10.1155/2007/35387)
 45. Josephs-Spaulding J, Krogh TJ, Rettig HC, Lyng M, Chkonia M, Waschina S, et al. Recurrent urinary tract infections: Unraveling the complicated environment of uncomplicated rUTIs. *Front Cell Infect Microbiol*. 2021; 11: 562525. DOI: [10.3389/fcimb.2021.562525](https://doi.org/10.3389/fcimb.2021.562525)
 46. Boeri L, Capogrosso P, Ventimiglia E, Scano R, Graziottin A, Dehò F, et al. Six out of ten women with recurrent urinary tract infections complain of distressful sexual dysfunction—A case-control study. *Sci rep*. 2017; 7: 44380. DOI: [10.1038/s41598-017-04380-0](https://doi.org/10.1038/s41598-017-04380-0)
 47. Chen YC, Lee WC, and Chuang YC. Emerging non-antibiotic options targeting uropathogenic mechanisms for recurrent uncomplicated urinary tract infection. *Int J Mol Sci*. 2023; 24(8): 7055. DOI: [10.3390/ijms24087055](https://doi.org/10.3390/ijms24087055)
 48. Chee WJ, Chew SY, and Than LT. Vaginal microbiota and the potential of *Lactobacillus* derivatives in maintaining vaginal health. *Microb Cell Factories*. 2020; 19: 203. Available at: <https://link.springer.com/article/10.1186/s12934-020-01464-4>
 49. Watson RA. Enlisting probiotics to combat recurrent urinary tract infections in women—A military strategy for meeting the challenge. *Antibiotics*. 2023; 12(1): 167. DOI: [10.3390/antibiotics12010167](https://doi.org/10.3390/antibiotics12010167)
 50. Graham K, Stack H, and Rea R. Safety, beneficial and technological properties of enterococci for use in functional food applications—a review. *Crit Rev Food Sci Nutr*. 2020; 60(22): 3836-3861. DOI: [10.1080/10408398.2019.1709800](https://doi.org/10.1080/10408398.2019.1709800)
 51. Chowdhury AH, Adiamah A, Kushairi A, Varadhan KK, Krznaric Z, Kulkarni AD, et al. Perioperative probiotics or synbiotics in adults undergoing elective abdominal surgery: A systematic review and meta-analysis of randomized controlled trials. *Ann surg*. 2020; 271(6): 1036-1047. Available at: https://journals.lww.com/annalsurgery/Fulltext/2020/06000/Perioperative_Probiotics_or_Synbiotics_in_Adults.12.aspx?context=LatestArticles
 52. Blaabjerg S, Artzi DM, and Aabenhus R. Probiotics for the prevention of antibiotic-associated diarrhea in outpatients—a systematic review and meta-analysis. *Antibiotics*. 2017; 6(4): 21. DOI: [10.3390/antibiotics6040021](https://doi.org/10.3390/antibiotics6040021)
 53. Kothari D, Patel S, and Kim SK. Probiotic supplements might not be universally-effective and safe: A review. *Biomed Pharmacother*. 2019; 111: 537-547. DOI: [10.1016/j.biopha.2018.12.104](https://doi.org/10.1016/j.biopha.2018.12.104)
 54. Reyna-Figueroa J, Barrón-Calvillo E, García-Parra C, Galindo-Delgado P, Contreras-Ochoa C, Lagunas-Martínez A, et al. Probiotic supplementation decreases chemotherapy-induced gastrointestinal side effects in patients with acute leukemia. *J Pediatr Hematol Oncol*. 2019; 41(6): 468-472. DOI: [10.1097/MPH.0000000000001497](https://doi.org/10.1097/MPH.0000000000001497)
 55. Wilkins T, and Sequoia J. Probiotics for gastrointestinal conditions: A summary of the evidence. *Am Fam Physician*. 2017; 96(3): 170-178. Available at: <https://europepmc.org/article/med/28762696>
 56. Schreck Bird A, Gregory PJ, Jalloh MA, Risoldi Cochrane Z, and Hein DJ. Probiotics for the treatment of infantile colic: A systematic review. *J Pharm Pract*. 2017; 30(3): 366-374. DOI: [10.1177/0897190016634516](https://doi.org/10.1177/0897190016634516)
 57. Di Gioia D, and Biavati B. Probiotics and prebiotics in animal health and food safety: Conclusive remarks and future perspectives. In Di Gioia D, Biavati B, editors. *Probiotics and prebiotics in animal health and food safety*. Springer, Cham; 2018. p. 269-273. Available at: https://link.springer.com/chapter/10.1007/978-3-319-71950-4_11#citeas
 58. Roobab U, Batool Z, Manzoor MF, Shabbir MA, Khan MR, and Aadil RM. Sources, formulations, advanced delivery and health benefits of probiotics. *Curr Opin Food*. 2020; 32: 17-28. DOI: [10.1016/j.cofs.2020.01.003](https://doi.org/10.1016/j.cofs.2020.01.003)
 59. Merrick B, Allen L, Zain NM, Forbes B, Shawcross DL, and Goldenberg SD. Regulation, risk and safety of faecal microbiota transplant. *Infect Prev Pract*. 2020; 2(3): 100069. DOI: [10.1016%2Fj.infpip.2020.100069](https://doi.org/10.1016%2Fj.infpip.2020.100069)
 60. Kong Y, Liu Z, Xiao Q, Wu F, Hu L, Deng X, and Chen T. Protective effects of engineered *Lactobacillus crispatus* on intrauterine adhesions in mice via delivering CXCL12. *Front Immunol*. 2022; 13: 905876. DOI: [10.3389/fimmu.2022.905876](https://doi.org/10.3389/fimmu.2022.905876)
 61. Jantarathin S, Borompichaichartkul C, and Sanguandekul R. Microencapsulation of probiotic and prebiotic in alginate-chitosan capsules and its effect on viability under heat process in shrimp feeding. *Mater Today: Proc*. 2017; 4(5 part 2): 6166-6172. DOI: [10.1016/j.matpr.2017.06.111](https://doi.org/10.1016/j.matpr.2017.06.111)
 62. Kustrimovic N, Bombelli R, Baci D, and Mortara L. Microbiome and prostate cancer: A novel target for prevention and treatment. *Int J Mol Sci*. 2023; 24(2): 1511. DOI: [10.3390/ijms24021511](https://doi.org/10.3390/ijms24021511)